Andy Clark
Board of Director
Pharmaceutical Sciences
SolAeroMed Inc.
Canada
Biography
Dr. Andy Clark, Ph.d. has been Chief Technology Officer and Vice President of Respira Therapeutics, Inc. since February 2015. Dr. Clark serves as Chief Technical Officer of Novartis. Dr. Clark serves as Scientific Advisor of ALRISE Biosystems GmbH. He served as Chief Technology Officer at Nektar Therapeutics (formerly Inhale Therapeutic Systems). He is a trained physicist with over 30+ years experience developing some of the pharmaceutical industries’ most novel inhalation products including Pulmozyme®, the first inhaled protein, Exubera® the first inhaled insulin, and Tobi Podhaler®, the first inhaled dry powder antibiotic. Dr. Andy Clark, Ph.d. has been Chief Technology Officer and Vice President of Respira Therapeutics, Inc. since February 2015. Dr. Clark serves as Chief Technical Officer of Novartis. Dr. Clark serves as Scientific Advisor of ALRISE Biosystems GmbH. He served as Chief Technology Officer at Nektar Therapeutics (formerly Inhale Therapeutic Systems). He is a trained physicist with over 30+ years experience developing some of the pharmaceutical industries’ most novel inhalation products including Pulmozyme®, the first inhaled protein, Exubera® the first inhaled insulin, and Tobi Podhaler®, the first inhaled dry powder antibiotic.
Research Interest
Pharmaceutical Sciences
